TIKETNCT06487663

TACE Combined With Immune Checkpoint Inhibitors for Liver Malignant Tumors

StatusUnknown

PhaseNot applicable

Primary completionOct 27, 2025 (estimated)

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

Minor Changed Nov 1, 2026 Registry marked status Unknown (sponsor has not verified the record since Jun 2024); last known: Recruiting
Jun 27, 2024 Study First Submitted

PFS

Timeframe: 3 years

ORR

TACE combined ICIExperimental

TACE combined ICI

Procedures: TACE with ICI

1 site in 1 country

This study will evaluate the efficacy and safety of TACE combined with immune checkpoint inhibitors to treat unresectable hepatocellular carcinoma.

Enrollment: 40 participants (estimated)
Started: Oct 27, 2020
Study completion: Oct 27, 2026 (estimated)
Eligibility: 18 to 75, all sexes, no healthy volunteers
Design: Interventional, open label, treatment
Conditions: Carcinoma, Hepatocellular, Cholangiocarcinoma, Hepatocellular Carcinoma Non-resectable, Cholangiocarcinoma Non-resectable, Liver Metastases, Liver Malignant Tumors
Official title: Transcatheter Hepatic Artery Chemoembolization Combined With Immune Checkpoint Inhibitors for Liver Tumors
First posted: Jul 5, 2024
Registry updated: Jul 5, 2024
Last verified: Jun 2024
Record status: This record was last updated July 5, 2024 (before its estimated October 27, 2025 completion). Its status may not reflect the trial's current state.

View on ClinicalTrials.gov ↗